Anileridine

Summary

Anileridine (CHEMBL1201347) is an approved small-molecule opioid analgesic (ATC N01AH05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N01AH05
• Chemistry: 352.5 Da · C22H28N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201347
Name	Anileridine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8944
ChEBI	CHEBI:61203
ATC	N01AH05
Molecular formula	C22H28N2O2
Molecular weight	352.5
InChIKey	LKYQLAWMNBFNJT-UHFFFAOYSA-N

SMILES: CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3

IUPAC name: ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate

ChEBI definition: A piperidinecarboxylate ester that is the ethyl ester of isonipecotic acid in which the hydrogen α- to the carboxyl group is substituted by a phenyl group, and the hydrogen attached to the nitrogen is substituted by a 2-(4-aminophenyl)ethyl group.

Pharmacological roles (ChEBI): opioid analgesic, opioid receptor agonist.

Also known as: Adopol, Alidine, Anileridina, Anileridine, Apidol, IDS-NA-012, Leritin, Nipecotan, SID170465266, ANILERIDINE

Parent form; salt/anhydrous children: CHEMBL1200543, CHEMBL1201047

Patent coverage: 2,417 distinct patent families (10,470 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).